Product Images Alfuzosin Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 9 images provide visual information about the product associated with Alfuzosin Hydrochloride NDC 63629-2354 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
chemical-structure - chemical structure
figure-1 - figure 1
figure-2 - figure 2
The text describes a graph with two groups of participants (Placebo and Alfuzosin hydrochloride extended-release tablets) and the mean change from baseline in IPSS Total Symptom Score over 84 days of treatment. The data suggests that Alfuzosin is significantly more effective in reducing symptoms than placebo, with a p-value of less than 0.001.*
figure-3 - figure 3
The text describes a figure showing the mean change from baseline in IPSS Total Symptom Score in Trial 2, after 28 and 56 days of treatment with either a placebo or Alfuzosin hydrochloride extended-release tablets. The figure indicates that there was a statistically significant difference (p < 0.01) between the placebo group (N=152) and the Alfuzosin hydrochloride extended-release tablets group (N=137).*
figure-4 - figure 4
The text describes the mean change from baseline in IPSS Total Symptom Score in Trial 3, for a placebo and Aituzosin hydrochloride extended-release tablets group. The study spanned 28 and 56 days of treatment and the results suggest that there is a significant difference between the two groups.*
figure-5 - figure 5
This is a chart showing the mean change from the baseline in peak urine flow rate (mL/s) in Trial 1. The chart contains two groups: Placebo (N=167) and Alfuzosin hydrochloride extended-release tablets (N=170). There are three data points: 0, 28 and 56 days of treatment. The chart suggests significant improvement in peak urine flow rate with Alfuzosin hydrochloride extended-release tablets compared to placebo.*
figure-6 - figure 6
The figure shows the Mean Change from Baseline in Peak Urine Flow Rate (mL/s) during a trial in which 147 subjects received a placebo, and 136 subjects received atuzosin hydrochloride extended-release tablets. The treatment was administered for 84 days, and a statistically significant difference was observed between the two groups. No further information is available.*
figure-7 - figure 7
The text describes a clinical trial in which the efficacy of Alfuzosin hydrochloride extended-release tablets was evaluated. The trial had 151 participants and compared the effects with those of a placebo on the peak urine flow rate over a period of 84 days. The results showed no significant difference between the two groups, as indicated by p > 0.05, and a graph depicts the mean change from baseline.*
Label - lbl636292354
This is a medication called NILD with VSN #0516. It's a tablet that contains Alfuzosin Hydrochloride, which is used to treat certain bladder conditions in men. It's important to keep this medication out of reach of children and store it in a cool, dry place. The tablets come in a container that is resistant to light and moisture. The prescription contains 100 tablets, and it is only available with a prescription from a physician.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.